multiple dose studies [Design Issues]

posted by dshah  – India/United Kingdom, 2024-03-08 18:36 (42 d 16:56 ago) – Posting: # 23895
Views: 559

Hello Loky do!


❝ I have a solifenacin succinate/tamsulosin HCl bioequivalence study, I will perform a multiple-dose study for tamsulosin modified release for Europe, I'm a little confused about the planned washout for this study as there are no enough public assessment reports for the combination, should I take in account the solifenacin washout period also or to design on tamsulosin only is enough (i.e one-week washout between 2 periods from last dose)


As this is FDC- both the drug needs to be analyzed and thus also consider Solifenacin for washout consideration.

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,657 registered users;
86 visitors (0 registered, 86 guests [including 3 identified bots]).
Forum time: 12:32 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5